Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=26 Study of Pembrolizumab Following TACE in Primary Liver Carcinoma
Primary Liver Carcinoma
Primary: Incidence of Treatment-emergent Adverse Events (Safety and Tolerability) — 15 Participants
N/A N=105 Primary Cell Culture of Hepatic Tumorous Cells From Routine Fine-needle Aspiration
Hepatocellular Carcinoma
Primary: Correlation Between the Growth Speeds of the Cultured Cells and the AJCC TNM Stage (7th Eds) at Entering of the Study. — 21; 29; 14; 9 participants — p=< 0.005
Phase 2 N=23 A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
Advanced Hepatocellular Carcinoma · HCC · Liver Cancer
Primary: Time to Disease Progression — 8 months
Phase 2 N=47 Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
Hepatocellular Carcinoma · Liver Cancer
Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months
N/A N=77 Dose Escalation Study for Primary Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Number of Patients With DLTs — 0; 2; 1; 0 Participants
Phase 2 N=11 Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Liver Cancer
Primary: Number of Subjects Experiencing Adverse Events — 2 participants
Phase 2 N=50 Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
Liver Cancer · Metastatic Cancer
Primary: Time to Progression — 2.3; 7.2 Months
Phase 2 N=25 Treatment of Primary Liver Tumors With Electrochemotherapy (ECT)
Liver Cancer
Primary: Number of Participants With Toxicity Related to Electrochemotherapy — 20; 0; 0; 4 Participants
Phase 3 N=70 De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
Liver Carcinoma
Primary: Percentage of Participants Surviving at One and Four Years After Liver Transplant — 85; 77 percentage of participants
N/A N=109 STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
Localized Hepatocellular Carcinoma
Primary: Number of Participants With Objective Tumor Response at 6 Months by MRI (Magnetic Resonance Imaging) — 75; 73 participants
Phase 2 N=172 PI-88 in Hepatocellular Carcinoma After Hepatectomy
Carcinoma, Hepatocellular
Primary: Tumour Non-recurrence Rate — 32; 40; 35 Participants — p=0.072
Phase 2 N=22 Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Liver Cancer
Primary: Median Overall Survival — 31.1 months
N/A N=23 Stereotactic Body Radiotherapy for Liver Tumors
Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma
Primary: Local Tumor Recurrence Rate — 4; 0 Participants
Phase 2 N=132 A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Overall Survival (OS): Number of Events — 15; 58; 31 Participants with events — p=0.837
Phase 2 N=60 Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib
Hepatocellular Carcinoma
Primary: Overall Response Rate — 6; 30; 17; 0 Participants
Phase 2 N=30 Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: One-Year Overall Survival Rate — 16 Participants
Phase 2 N=39 Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer
Liver Cancer
Primary: Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) — 1; 1; 17; 15 Participants
N/A N=76 Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Two Year Overall Survival — 65; 68 percentage of participants
Phase 3 N=720 Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Overall Survival — 289; 259 Days
Phase 2 N=59 Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
Hepatocellular Carcinoma · Liver Cancer
Primary: Progression-free Survival (PFS) Rate — 64 percentage of participants
Phase 2 N=24 Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Liver Cancer
Primary: Maximum Tolerated Dose (Phase I) — 2; 3; 0; 0 Participants
Phase 2 N=54 A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Biliary Tract Neoplasms · Liver Cancer · Hepatocellular Carcinoma
Primary: 6 Month Progression Free Survival (PFS) — 2.8; NA Months
Phase 2 N=41 Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
Liver Cancer
Primary: Response Rate by Recist Criteria — 6 participants
Phase 3 N=230 Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients
Hepatocellular Carcinoma
Primary: Recurrence Free Survival(RFS) — 44.0; 30.0 months — p=0.01
Phase 2 N=30 A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Proportion of Subjects Achieving Disease Control (Non-progressive Disease) at 8 Weeks After Initiation of Treatment — 0.7273; 0.6429 Proportion of evaluable participants
Phase 3 N=458 Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Carcinoma, Hepatocellular
Primary: Time to Progression (TTP) — 164; 112 days
Phase 2 N=76 Proton Beam Therapy for Treatment of Hepatocellular Carcinoma
Liver Cancer · Hepatocellular Carcinoma
Primary: 3-year Survival Without Tumor Progression for Patients Within the Milan Criteria — 60 percentage of participants
Phase 4 N=1,044 Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy
Hepatic Carcinoma
Primary: Incidence of Recurrence and Metastasis After Hepatectomy — 428; 155; 258; 161 Participants — p=0.0001
Phase 2 N=37 An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer
Liver Neoplasms · Unresectable Hepatocellular Carcinoma
Primary: Best Overall Response — 0; 1; 15; 11 participants